Company Description
NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain.
Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.
The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital.
The company was founded in 2015 and is based in Wilmington, Delaware.
Country | United States |
Founded | 2015 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 2 |
CEO | Stephen H. Willard Esq. |
Contact Details
Address: 1201 Orange Street, Suite 600 Wilmington, Delaware 19801 United States | |
Phone | 484-254-6134 |
Website | nrxpharma.com |
Stock Details
Ticker Symbol | NRXP |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001719406 |
CUSIP Number | 089482103 |
ISIN Number | US6294441000 |
Employer ID | 82-2844431 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Jonathan C. Javitt M.D., M.P.H. | Co-Founder, Chief Scientist Officer and Chairman |
Stephen H. Willard Esq. | Acting Corporate Secretary, Chief Executive Officer and Director |
Dr. Riccardo Panicucci Ph.D. | Chief Technology Officer |
Dr. Seth L. Van Voorhees Ph.D. | Treasurer |
Richard Clavano Narido | Interim Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer |
Suzanne Messere | Investor Relations |
Dr. Philip T. Lavin Ph.D. | Chief Methodologist |
Dr. Dennis K. McBride Ph.D. | Chief Strategy Officer and Senior Scientist |
Matthew Patrick Duffy | Chief Business Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
May 16, 2024 | 8-K | Current Report |
May 14, 2024 | 10-Q | Quarterly Report |
Apr 30, 2024 | 8-K | Current Report |
Apr 29, 2024 | 10-K/A | [Amend] Annual report |
Apr 19, 2024 | 8-K | Current Report |
Apr 19, 2024 | 424B5 | Filing |
Apr 18, 2024 | 424B5 | Filing |
Apr 15, 2024 | 8-K | Current Report |
Apr 15, 2024 | 424B3 | Prospectus |
Apr 15, 2024 | 424B3 | Prospectus |